Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 1999

View Archived Issues

Kurtoxin-1 available for licensing from NIH

Licensing/CRADA opportunity from NIH: eosinophil-derived neutralizing agent

Recombinant Velosulin BR approved in U.S. for diabetes

Amgen presents Q2 highlights

Draxis Health completes acquisition of eight Elan neurology products

Valentis initiates phase I/II trial of IL-12 gene therapy

Q2 results, clinical progress reported by Icos

Paxene approved for E.U. marketing; Paxoral shows positive results in phase I

FDA Advisory Committee votes against recommending Allergan therapy for dry eye disease

Arylthiazolidinedione PPAR agonists discovered at Merck

Neuroprotective agents from AstraZeneca possess novel mechanism of action

Triazine compound with anticonvulsant, analgesic and neuroprotective effects

Alcon's new prostaglandin analogues for glaucoma

Sunrise LTK System not recommended for FDA approval

Benzazepines synthesized at Zambon useful as antiallergic/antiinflammatory agents

MCP-1 receptor antagonists in early development at Takeda

Bexxar assigned priority review status by FDA

Potent melatonin receptor ligands synthesized and tested at ADIR

Novel AMPA/kainate antagonist protective in models of global and focal cerebral ischemia

Pharmacological profile of new NMDA receptor antagonist selective for NR2B subunit

BRAIN ' 99: dexanabinol may have potential in essential tremor

Cortecs and Towa terminate collaboration for Macritonin, milestone payment received by Cortecs

News from BRAIN '99: inhibition of VEGF activity represents novel antiischemic therapeutic strategy

SR-146131: new, orally active, potent and selective CCK1 agonist

Austrian lab presents preliminary results with new AChE inhibitor: SPH-1286

Novel silent antagonist of vascular 5-HT1B-like receptors identified during collaboration

Centocor to join the Johnson & Johnson family of companies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...